Soluble urokinase plasminogen activator receptor in blood transfusion components
暂无分享,去创建一个
[1] T. Mynster. Blood transfusion-induced immunomodulation--is storage time important? , 2003, Danish medical bulletin.
[2] N. Brünner,et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] S. Rabbani,et al. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. , 2002, Cancer research.
[4] N. Brünner,et al. Soluble Urokinase Plasminogen Activator Receptor Measurements: Influence of Sample Handling , 2001, The International journal of biological markers.
[5] U. Weidle,et al. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. , 2001, The Biochemical journal.
[6] H. Nielsen,et al. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. , 2001, Gynecologic oncology.
[7] E. Rondeau. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. , 2001, Kidney international.
[8] N. Brünner,et al. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. , 2001, European journal of cancer.
[9] E. Vamvakas,et al. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? , 2001, Blood.
[10] L. Van De Watering,et al. Perioperative blood transfusions, with or without allogeneic leucocytes, relate to survival, not to cancer recurrence , 2001, The British journal of surgery.
[11] H. Ullum,et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. , 2000, Blood.
[12] Maciej Pysz. Blood transfusions in breast cancer patients undergoing mastectomy: Possible importance of timing , 2000, Journal of surgical oncology.
[13] I. Christensen,et al. Effects of the combination of blood transfusion and postoperative infectious complications on prognosis after surgery for colorectal cancer , 2000, The British journal of surgery.
[14] R. McLeod,et al. Allogeneic Red Blood Cell Transfusion Is an Independent Risk Factor for the Development of Postoperative Bacterial Infection , 2000, Vox Sanguinis.
[15] M. Mann,et al. A Urokinase Receptor-associated Protein with Specific Collagen Binding Properties* , 2000, The Journal of Biological Chemistry.
[16] N. Brünner,et al. Soluble vascular endothelial growth factor in various blood transfusion components , 1999, Transfusion.
[17] D. Rifkin,et al. Cellular glycosylphosphatidylinositol‐specific phospholipase D regulates urokinase receptor shedding and cell surface expression , 1999, Journal of cellular physiology.
[18] H. Nielsen,et al. Reduction of bioactive substances in stored donor blood: prestorage versus bedside leucofiltration , 1999, European journal of haematology.
[19] H. Nielsen,et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. , 1999, Journal of the National Cancer Institute.
[20] F. Blasi. The urokinase receptor. A cell surface, regulated chemokine , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[21] H. Nielsen,et al. Bioactive substances in buffy‐coat‐derived platelet pools stored in platelet‐additive solutions , 1998, British journal of haematology.
[22] H. Nielsen. Clinical Impact of Bioactive Substances in Blood Components: Implications for Leukocyte Filtration , 1998, Transfusion Medicine and Hemotherapy.
[23] R. Stephens,et al. The urokinase receptor , 1998 .
[24] N. Brünner,et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. , 1998, Cancer research.
[25] R. Medcalf,et al. The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule. , 1998, European journal of biochemistry.
[26] Michael V. Doyle,et al. Regulation of Integrin Function by the Urokinase Receptor , 1996, Science.
[27] H. Nielsen,et al. Leucocyte and platelet derived bioactive substances in stored standard platelet concentrates , 1996, European journal of haematology.
[28] F. Blasi,et al. Proteolytic cleavage of the urokinase receptor substitutes for the agonist‐induced chemotactic effect. , 1996, The EMBO journal.
[29] N. Brünner,et al. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion , 1995 .
[30] H. J. Nielsen,et al. Detrimental effects of perioperative blood transfusion , 1995, The British journal of surgery.
[31] M. Gyetko,et al. The urokinase receptor is required for human monocyte chemotaxis in vitro. , 1994, The Journal of clinical investigation.
[32] N. E. Hansen,et al. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. , 1994, Blood.
[33] L. Lund,et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. , 1992, The Journal of biological chemistry.
[34] N. E. Hansen,et al. A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. , 1992, European journal of biochemistry.
[35] P. Walsh,et al. Prostate cancer recurrence in radical surgery patients receiving autologous or homologous blood , 1992, Transfusion.
[36] M. Ploug,et al. Cell‐induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2‐terminal domain of the urokinase receptor , 1991, FEBS letters.
[37] D. Fry,et al. Breast cancer survival and perioperative blood transfusion. , 1989, Surgery.
[38] W. Russell,et al. Histamine levels in stored human blood , 1984, Transfusion.
[39] T. van der Poll,et al. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. , 2001, Kidney international.
[40] K. Preissner,et al. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. , 1998, Blood.
[41] F. Blasi. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion , 1994 .
[42] L. Kołodziejski,et al. Blood transfusion and survival after surgery for stage I and II breast cancer. , 1993, Neoplasma.
[43] W. Ross. Blood transfusions and prognosis in colorectal cancer. , 1993, The New England journal of medicine.
[44] K. Danø,et al. Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.